BlackRock Advisors’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

BlackRock Advisors’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$78K	Buy	5,918 +405	+7%	+$5.42K	﹤0.01%	3127
2016 Q3	$80K	Hold	5,513	–	–	﹤0.01%	3110
2016 Q2	$66K	Buy	5,513 +749	+16%	+$12K	﹤0.01%	3147
2016 Q1	$89K	Buy	4,764 +562	+13%	+$9.32K	﹤0.01%	2972
2015 Q4	$90K	Sell	4,202 -2,265	-35%	-$47.9K	﹤0.01%	2971
2015 Q3	$109K	Buy	6,467 +387	+6%	+$9.62K	﹤0.01%	3059
2015 Q2	$228K	Buy	+6,080	New	+$196K	﹤0.01%	2726

Other funds holding CBMG

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock Advisors's CBMG Position: Q4 2016 in Review

BlackRock Advisors increased its Cellular Biomedicine Group, Inc. (CBMG) stake by 7.3% in Q4 2016, buying an estimated $5.42K and bringing the position to 5,918 shares worth $78K. The position accounts for ﹤0.01% of the portfolio, ranked #3127.

BlackRock Advisors first reported a position in CBMG in Q2 2015 and has held it in 7 quarters since. The position peaked at $228K in Q2 2015. 38 funds tracked by Wall St. Rank hold CBMG as of Q4 2016.

BlackRock Advisors held 5,918 shares of Cellular Biomedicine Group, Inc. worth $78K as of Q4 2016.
BlackRock Advisors bought 405 Cellular Biomedicine Group, Inc. shares in Q4 2016, an estimated $5.42K.
Cellular Biomedicine Group, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3127 holding.
BlackRock Advisors first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's Cellular Biomedicine Group, Inc. position peaked at $228K in Q2 2015.
38 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.